Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Christopher

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Pharmaceutical Patent Analyst|November 19, 2013
Orexin receptor antagonistsJohn A Christopher
Pharmaceutical Patent Analyst|December 10, 2014
Small-molecule antagonists of the orexin receptorsJohn A Christopher
Current Opinion in Pharmacology|July 12, 2016
The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniquesBenjamin G Tehan, John A Christopher
Expert Opinion on Therapeutic Patents|January 4, 2013
Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692)John A Christopher, Miles S Congreve
Current Topics in Medicinal Chemistry|July 25, 2016
Potential for the Rational Design of Allosteric Modulators of Class C GPCRsJohn A Christopher, Andrew S Doré, Benjamin G Tehan
Advances in Pharmacology (San Diego, Calif.)|May 18, 2020
Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulatorsKirstie A Bennett, John A Christopher, Benjamin G Tehan
Chemmedchem|December 20, 2013
Structure-based and fragment-based GPCR drug discoveryStephen P Andrews, Giles A Brown, John A Christopher
Beilstein Journal of Organic Chemistry|October 23, 2008
Perhalogenated pyrimidine scaffolds. Reactions of 5-chloro-2,4,6-trifluoropyrimidine with nitrogen centred nucleophilesEmma L Parks, Graham Sandford, John A Christopher, et al.
Current Topics in Medicinal Chemistry|September 30, 2015
Orexin Receptor Antagonists: Historical Perspectives and Future OpportunitiesStephen P Andrews, Sarah J Aves, John A Christopher, et al.
Journal of Medicinal Chemistry|October 3, 2019
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 ReceptorsRie Suzuki, Giles A Brown, John A Christopher, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Pharmaceutical Patent Analyst|November 19, 2013
Orexin receptor antagonistsJohn A Christopher
Pharmaceutical Patent Analyst|December 10, 2014
Small-molecule antagonists of the orexin receptorsJohn A Christopher
Current Opinion in Pharmacology|July 12, 2016
The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniquesBenjamin G Tehan, John A Christopher
Expert Opinion on Therapeutic Patents|January 4, 2013
Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692)John A Christopher, Miles S Congreve
Current Topics in Medicinal Chemistry|July 25, 2016
Potential for the Rational Design of Allosteric Modulators of Class C GPCRsJohn A Christopher, Andrew S Doré, Benjamin G Tehan
Advances in Pharmacology (San Diego, Calif.)|May 18, 2020
Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulatorsKirstie A Bennett, John A Christopher, Benjamin G Tehan
Chemmedchem|December 20, 2013
Structure-based and fragment-based GPCR drug discoveryStephen P Andrews, Giles A Brown, John A Christopher
Beilstein Journal of Organic Chemistry|October 23, 2008
Perhalogenated pyrimidine scaffolds. Reactions of 5-chloro-2,4,6-trifluoropyrimidine with nitrogen centred nucleophilesEmma L Parks, Graham Sandford, John A Christopher, et al.
Current Topics in Medicinal Chemistry|September 30, 2015
Orexin Receptor Antagonists: Historical Perspectives and Future OpportunitiesStephen P Andrews, Sarah J Aves, John A Christopher, et al.
Journal of Medicinal Chemistry|October 3, 2019
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 ReceptorsRie Suzuki, Giles A Brown, John A Christopher, et al.
Pageof 4